Royalty Pharmaìs Acquisition of Royalty Interest from GSK

Dechert advised Royalty Pharma on the deal.

Royalty Pharma plc executed its acquisition of a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million and up to $50 million in additional payments contingent on the achievement of regulatory approvals of cabozantinib for prostate cancer and lung cancer in the U.S. and Europe.

Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.

The Dechert team advising Royalty Pharma on IP-related matters included intellectual property partner Carl A. Morales (Picture), Ph.D., associate Blaine M. Hackman, Ph.D. and patent agent Todd K. Macklin, Ph.D.  

Involved fees earner: Blaine Hackman – Dechert; Todd Macklin – Dechert; Carl Morales – Dechert;

Law Firms: Dechert;

Clients: Royalty Pharma;

Print Friendly, PDF & Email

Author: Martina Bellini